Workflow
Shandong Weigao Blood Purification Products(603014)
icon
Search documents
威高血净成功登陆A股,上市首日大涨56%
Jing Ji Guan Cha Wang· 2025-05-19 08:22
2025年5月19日,国内血液透析领域龙头企业——山东威高血液净化制品股份有限公司(以下简称"威高血净",股票代码:603014)正式登陆上交所主板。 上市首日股价表现强劲,盘中最高涨幅达88.64%,最终收报41.41元/股,涨幅56.26%,总市值突破170亿元,展现出资本市场对其行业地位及未来发展的高 度认可。 作为国内最早自主研发血液透析器的企业之一,威高血净在中空纤维膜技术、生物相容性优化等核心领域取得重大突破,成功打破外资品牌长期垄断。据弗 若斯特沙利文数据,2023年,威高血净在国内血液透析器市场占有率32.5%、透析管路市场占有率31.8%,均位居行业前列。 业绩稳健增长,政策红利助力长期发展 近年来,随着终末期肾病(ESRD)纳入医保及国产替代政策推动,威高血净业绩持续向好。2022-2024年,公司营收分别为34.26亿元、35.32亿元和36.04亿 元,归母净利润达3.15亿元、4.42亿元和4.49亿元,盈利能力稳步提升。 机构预测,到2030年,中国血液透析市场规模有望突破500亿元,而威高血净作为行业龙头,有望在基层医疗渗透率提升及国际化布局的双轮驱动下,实现 长期稳健增长。 未 ...
正式上市!国产血液净化龙头企业
思宇MedTech· 2025-05-19 07:59
Core Viewpoint - The blood purification market in China is experiencing significant growth, driven by an increasing number of patients with uremia and an aging population, with a projected annual growth rate of 15% [2] Group 1: Market Overview - The blood purification market in China is expected to grow from 11.6 billion in 2019 to 21.1 billion by 2025, and reach 51.515 billion by 2030, indicating substantial growth potential [2] - The company Weigao Blood Purification holds a leading market share in blood dialysis devices, with 32.5% in blood dialysis filters and 31.8% in blood dialysis tubing, and a second position in dialysis machines with a 24.6% market share [2] Group 2: Financial Performance - Weigao Blood Purification's revenue from 2022 to 2024 is projected to be 3.426 billion, 3.532 billion, and 3.604 billion respectively, with net profits of 315 million, 442 million, and 449 million, demonstrating stable growth [3] - The net profit growth in 2023 was 40.36%, followed by a slight increase of 1.65% in 2024, aligning with the industry's strategy of "volume for price" under the background of centralized procurement [3] Group 3: Company Overview - Weigao Blood Purification is the fourth listed company under Weigao Group, focusing on the research, production, and sales of blood purification medical products, covering the entire industry chain of blood dialysis and peritoneal dialysis [5] - The company collaborates with international firms like Nikkiso and Terumo to enhance the technology level of high-end products [5] Group 4: Product Line Development - The company launched its first self-developed blood dialysis filter in 2005, breaking the overseas monopoly, and has since introduced various innovative products, including the first polysulfone membrane dialysis filter in 2008 and the high-flux HF series in 2013 [6][8] - Blood dialysis tubing sales increased from 30.06 million sets in 2022 to 39 million sets in 2024, with revenue rising from 414 million to 495 million, marking a growth of approximately 29.74% [9]
威高血净上市首日涨56% 募资10.9亿元华泰联合建功
Zhong Guo Jing Ji Wang· 2025-05-19 07:34
Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. successfully listed on the Shanghai Stock Exchange, with a closing price of 41.41 yuan, reflecting a 56.26% increase on the first day of trading [1] Company Overview - Weigao Blood Purification was established in 2004 and focuses on the research, production, and sales of blood purification medical products, including hemodialyzers, blood dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1] - The company is one of the domestic manufacturers with the most comprehensive product lines in the blood purification medical products sector [1] Shareholding Structure - Prior to the issuance, Weigao Group held 46.39% of Weigao Blood Purification's shares, remaining the controlling shareholder after the issuance with 41.75% [1] - Chen Xueli, through Weigao Group, Weigao Co., and Weihai Kaide, controlled 83.70% of Weigao Blood Purification before the issuance, and continues to control 75.33% after the issuance [1] IPO Details - The total number of shares issued was 41,139,407, accounting for 10.00% of the total share capital post-issuance, with an issuance price of 26.50 yuan per share [5] - The total amount raised from the issuance was 1.09 billion yuan, with a net amount of 977.89 million yuan, which is 373.11 million yuan less than the original plan [6] Fund Utilization - The raised funds are intended for several projects, including: - Intelligent production construction project for blood purification (34.26 million yuan) - Dialyzer production project in Ganzhou (22.67 million yuan) - R&D center for new high-performance consumables (28.54 million yuan) - Digital information technology platform construction (9.87 million yuan) - Working capital supplementation (40 million yuan) [7] Issuance Costs - The total issuance costs amounted to 112.30 million yuan, excluding VAT, with underwriting and sponsorship fees of 78.18 million yuan [8]
威高血净上市募资超10亿,市值近180亿,华兴资本等机构入股
Sou Hu Cai Jing· 2025-05-19 06:03
Core Viewpoint - Weigao Blood Purification Products Co., Ltd. successfully listed on the Shanghai Stock Exchange, raising approximately 1.09 billion yuan, with a significant initial stock price increase of 88.6% compared to the issue price [1][5]. Financial Performance - The company reported steady revenue growth from 2021 to 2023, with revenues of 2.91 billion yuan, 3.43 billion yuan, and 3.53 billion yuan respectively. Net profits for the same years were 260 million yuan, 315 million yuan, and 442 million yuan [1]. - For the first half of 2024, the company achieved revenue of 1.626 billion yuan and net profit of 200 million yuan, with expectations of a full-year revenue of 3.6 billion yuan, a 2% increase year-on-year [2]. Product and Market Position - Weigao Blood Purification specializes in the research, production, and sales of medical blood purification products, including hemodialysis devices and peritoneal dialysis solutions, making it one of the most comprehensive manufacturers in the domestic market [1]. - The company primarily utilizes a distribution model for sales, with sales through this model accounting for approximately 67.76% to 72.74% of its main business revenue over recent years [3]. Shareholding Structure - The largest shareholder, Weigao Group, holds 41.75% of the shares post-IPO, while other significant shareholders include Weigao Co., Ltd. and Weihai Kaide [4]. - Institutional investors such as Nichijisou and Grand Begonia also hold shares, indicating a diversified ownership structure [3][4]. Future Outlook - The successful IPO is expected to enhance the company's financial support for future development and strengthen its competitive position in the blood purification medical products sector [5].
5分钟!暴涨超1100%
Market Overview - A-shares showed mixed performance on the morning of May 19, with the real estate sector being a significant highlight, where multiple stocks hit the daily limit up [1][2][3] - The Hong Kong market exhibited relatively flat performance, but some individual stocks experienced significant volatility, notably China Financial International, which surged over 1100% during the session [2][9] Real Estate Sector - The real estate sector led the A-share market with a gain of over 2%, with stocks such as Konggang Co., Ltd., Shahe Co., Ltd., and others reaching their daily limit up [3] - In April 2025, the sales prices of commercial residential properties in 70 major cities remained stable or slightly decreased month-on-month, with the year-on-year decline narrowing [3] - In first-tier cities, new residential property prices were flat month-on-month, with Beijing and Shanghai seeing slight increases of 0.1% and 0.5%, while Guangzhou and Shenzhen experienced minor declines [3] New Stock Listings - Two new stocks, Taili Technology and Weigao Blood Purification, were listed today, with Taili Technology seeing a peak increase of over 200% [5][6] - Taili Technology focuses on new materials and vacuum technology, offering a range of home storage products and solutions [6] - Weigao Blood Purification, established in 2004, specializes in blood purification medical products, holding significant market shares in various segments, including 32.5% in blood dialysis devices [7][8] Hong Kong Market Activity - China Financial International's stock surged over 1100% after meeting all resumption guidelines and being allowed to resume trading [9][10] - The company addressed issues that previously led to audit opinions and has committed to providing sufficient data for investors to evaluate its financial status [10]
山东富豪IPO敲钟了,威高血净市值200亿
Sou Hu Cai Jing· 2025-05-19 04:14
Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. (Weigao Blood Purification) officially listed on the Shanghai Stock Exchange with an initial price of 26.50 CNY per share, experiencing an opening surge of 88.64%, and reaching a market capitalization exceeding 20 billion CNY [1][6]. Company Overview - Weigao Blood Purification is a subsidiary of Weigao Group, founded by Chen Xueli, who has a remarkable entrepreneurial journey starting from assembling infusion devices in rural Shandong [2][3]. - The company specializes in blood purification, particularly focusing on hemodialysis and peritoneal dialysis, with a comprehensive product line including blood dialysis machines and related products [7]. Market Position - In 2022, Weigao Blood Purification held a market share of 32.5% in the domestic blood dialysis device market and 32.8% in blood dialysis tubing, ranking first in the industry [5]. - The company’s products are utilized in over 6,000 hospitals and dialysis centers across China [5]. Financial Performance - Projected revenues for Weigao Blood Purification from 2022 to 2024 are 34.26 billion CNY, 35.32 billion CNY, and 36.04 billion CNY, respectively, with net profits of 3.15 billion CNY, 4.42 billion CNY, and 4.49 billion CNY [7]. - The blood dialysis devices account for over 50% of the company's revenue, with sales figures of 17.47 billion CNY, 18.34 billion CNY, and 18.38 billion CNY during the same period [7]. Technological Advancements - Weigao Blood Purification has developed core technologies for hollow fiber membranes used in dialysis, achieving international advanced levels in key performance indicators [4]. - The company launched China's first self-branded blood dialysis device, breaking the foreign monopoly in the market [5]. Investment and Financing - Prior to its IPO, Weigao Blood Purification conducted a single round of financing, attracting notable investors including Huaxing New Economy Fund and Liu Xiaodan's Chen Yi Investment [2][9]. - The company had previously attempted to list on the Hong Kong Stock Exchange in 2022 but later shifted to the A-share market for a successful listing [10]. Founder and Leadership - Chen Xueli, the founder, controls 83.70% of Weigao Blood Purification through various entities, marking this as his fourth listed company [11][12]. - Under his leadership, Weigao Group has expanded to four publicly listed companies, with a combined market capitalization nearing 60 billion CNY [12].
财达证券晨会纪要-20250519
Caida Securities· 2025-05-19 03:04
Summary of Key Points Core Insights - The report highlights the upcoming listings and trading activities of several companies on May 19, 2025, indicating a busy market day with multiple new entries [1][2][3]. Upcoming Listings - Company 001390 Guqi Fur Material will be available for online subscription on May 19, 2025 [1]. - Companies 301595 N Taili and 603014 N Weigao will officially list on the same day, with allocations for general institutional investors [1]. - Company 920060 Wanyuantong will also list on May 19, 2025, specifically for the public portion [1]. Suspension Announcements - Company 002092 ST Zhongtai and 002259 ST Shengda will be suspended for one day due to the announcement of the withdrawal of other risk warnings [2]. - The Invesco Great Wall S&P Consumer Select ETF (QDII) and Guotai S&P 500 ETF will also be suspended until 10:30 AM on May 19, 2025, to protect investor interests [2]. - Company 300506 *ST Mingjia will be suspended for one day following the announcement of the withdrawal of delisting risk warnings [2]. Special Suspensions - Company 000151 Zhongcheng Co. will be suspended due to plans for issuing shares to acquire assets and raise matching funds, effective from May 16, 2025 [3]. - Company 000584 *ST Gongzhi and 000622 *ST Hengli will also face suspensions due to potential delisting risks and failure to disclose periodic reports within the legal timeframe [3]. - Company 002336 *ST Renle will be suspended for one day due to the announcement of potential delisting risks [3].
血液净化龙头「威高血净」正式登陆A股:开盘上涨超60%,华兴、晨壹为投资方
IPO早知道· 2025-05-19 02:46
打破外资血液透析医疗器械厂商垄断。 本文为IPO早知道原创 作者| Stone Jin 微信公众号|ipozaozhidao 据 IPO早知道消息, 山东威高血液净化制品股份有限公司 (以下简称 " 威高血净 ")于2025年5 月19日正式以"603014"为股票代码在上交所主板挂牌上市。 截至10:00,威高血净报于每股42.47元,较发行价上涨60.26%,市值超174亿元。 打破 外资血液透析医疗器械厂商 垄断 成立于 2004年的 威高血净 专注于 血液透析和腹膜透析两大赛道,辅以透析配套产品的销售,是 国内产品线最为丰富的血液净化医用制品厂商之一 。 其中, 威高血净的血液透析产品主要包括血 液透析器、血液透析管路以及血液透析机等,腹膜透析产品主要包括腹膜透析液等。 事实上, 在血液透析市场,外资血液透析医疗器械厂商主要包括费森尤斯医疗、百特医疗、贝朗医 疗、尼普洛等,曾占据国内血液透析医疗器械市场的主要份额。血液透析耗材方面,随着国产厂商的 研发实力和技术水平不断提高,国产品牌逐步崛起,市场竞争力不断增强,以威高血净为代表的国产 厂商正在血液透析器、血液透析管路等细分领域逐步实现国产替代。 根据 ...
N威高开盘上涨88.64%
Company Overview - N Weigao has been listed today with an opening price of 49.99 yuan, representing an increase of 88.64% from its issue price [2][3] - The company specializes in the research, production, and sales of medical products for blood purification [3] Financial Highlights - The total number of shares issued by the company is 41.1394 million, with an online issuance of 26.8545 million shares [3] - The issue price was set at 26.50 yuan per share, with an issuance price-to-earnings ratio of 24.82 times, compared to the industry average of 28.04 times [3] - The total funds raised from the initial public offering (IPO) amount to 1.09 billion yuan, which will be allocated to various projects including working capital, intelligent production construction, and the development of high-performance consumables [3] Market Performance - The effective subscription number for the online issuance reached 11.6331 million accounts, with a final winning rate of 0.03215719% [3] - Recent IPOs in the medical and biological sector have shown significant first-day performance, with N Weigao's opening increase being one of the highest [3][4]
今日上市:太力科技、威高血净
Zhong Guo Jing Ji Wang· 2025-05-19 00:56
Group 1: Tai Li Technology - Tai Li Technology focuses on the research and development of new materials and the industrial application of vacuum technology, with main products including vacuum storage, wall-mounted storage, modified atmosphere preservation, outdoor equipment, and safety protection [1] - Before the issuance, Shi Zhengbing directly held 60.03 million shares, accounting for 73.92% of the total shares, and indirectly controlled 82.31% of the company's shares through partnerships [1] - The total amount raised from this issuance is 461.54 million yuan, with a net amount of 369.52 million yuan after deducting issuance costs, allocated for the construction of production and logistics centers, R&D centers, information system upgrades, and working capital [1] Group 2: Weigao Blood Purification - Weigao Blood Purification focuses on two main areas: hemodialysis and peritoneal dialysis, and is one of the most comprehensive manufacturers of blood purification medical products in China [2] - Before the issuance, Weigao Group directly held 46.39% of the shares, and after the issuance, it holds 41.75%, remaining the controlling shareholder [2] - The total amount raised from this issuance is 1.09 billion yuan, with a net amount of 977.89 million yuan after deducting issuance costs, allocated for intelligent production construction, new product development, and digital information technology platform construction [2]